Download Helminth derived Immunodmodulator A therapeutic for immune-related diseases Overview

Helminth derived Immunodmodulator
A therapeutic for immune-related diseases
Overview
The technology relates to novel compositions and methods for modulating an immune response in order to prevent or treat disease and/or
conditions where T lymphocyte cells have a pathogenic role, such as Th1 or ThIL-17 mediated inflammatory conditions, chronic inflammatory
conditions and autoimmune diseases
Infection with Helminth parasites has been associated with immunosuppression and compromised T-cell responses. Fasciola hepatica
excretory/secretory (ES) components have also been shown to suppress Th1 responses induced by a whole cell B. pertussis vaccine. Furthermore,
ES component of F. hepatica stimulates the production of anti-inflammatory cytokines, such as IL-10, which can serve as potent modulators of the
immune response.
Advantages
Applications
• A method of preventing the onset and progression of
autoimmune diseases, inflammatory conditions or
immune mediated disorders
Novel immunomodulator for T Cell mediated inflammatory and autoimmune
diseases.
Asthma, arthrosclerosis, Alzheimer’s disease, type 2 diabetes and osteoarthritis
• Mechanism of action established through the
modulation of the T cell responses which are causative
of these immune mediated conditions
• No recombinant or artificial anti-inflammatory agent is
required, but a product that stimulates the body to make
its own anti-inflammatory cytokines
Market
Therapeutics: Synthesis, Formulation<
Processing and Drug Delivery
• Cells of the innate and adaptive immune system that
mediate inflammation also make these antiinflammatory cytokines in vivo, they are more likely to be
effective at the site of inflammation.
IP Status
US patent 8,105,601 granted
EP patent EP06821545.8 granted
• More natural immuno-stimulatory effects would be
induced as opposed to current treatments that are
immune compromising,
Opportunity
Research collaboration and/or
License
• Potential immunotherapeutics that focus on resetting the
balance of host regulatory to effector/pathogenic
immune responses to restore homeostasis without
globally suppressing the immune response
Researcher(s)
Technology and Patent Status
Prof. Kingston Mills
Development state: In research / Concept /
Idea • In development / Lab scale
Contact
Dr. Emily Vereker,
IP state: Patent(s) granted
MOG induced EAE model – attenuated by Fasciola Hepatica
J Immunol. 2009 Aug 1;183(3):1577-86.
Case Manager, Life Sciences
Clinical development phase: Target
validation
[email protected]
The opportunity
Reference:
This offer is available for: further research or
development support • Joint venture
agreement • License agreement • Privatepublic partnership
+353 1 896 4152
KM01-041-01